The prognostic significance was outperformed by the prognostic power of MCT4 expression and especially by that of DNA methylation at specific CpG sites in the SLC16A3 promoter region, corroborating the role of MCT4 as qualified prognostic biomarker for ccRCC. The gene discussed is SLC16A3; the disease is nonpapillary renal cell carcinoma.